Although the enzymatic activity of isocitrate dehydrogenase 1 (IDH1) was defined decades ago, its functions in vivo are not yet fully understood. Cytosolic IDH1 converts isocitrate to α-ketoglutarate (α-KG), a key metabolite regulating nitrogen homeostasis in catabolic pathways. It was thought that IDH1 might enhance lipid biosynthesis in liver or adipose tissue by generating NADPH, but we show here that lipid contents are relatively unchanged in both IDH1-null mouse liver and IDH1-deficient HepG2 cells generated using the CRISPR-Cas9 system. Instead, we found that IDH1 is critical for liver amino acid (AA) utilization. Body weights of IDH1-null mice fed a high-protein diet (HPD) were abnormally low. After prolonged fasting, IDH1-null mice exhibited decreased blood glucose but elevated blood alanine and glycine compared with wildtype (WT) controls. Similarly, in IDH1-deficient HepG2 cells, glucose consumption was increased, but alanine utilization and levels of intracellular α-KG and glutamate were reduced. In IDH1-deficient primary hepatocytes, gluconeogenesis as well as production of ammonia and urea were decreased. In IDH1-deficient whole livers, expression levels of genes involved in AA metabolism were reduced, whereas those involved in gluconeogenesis were up-regulated. Thus, IDH1 is critical for AA utilization in vivo and its deficiency attenuates gluconeogenesis primarily by impairing α-KG-dependent transamination of glucogenic AAs such as alanine.
Although the enzymatic activity of isocitrate dehydrogenase 1 (IDH1) was defined decades ago, its functions in vivo are not yet fully understood. Cytosolic IDH1 converts isocitrate to α-ketoglutarate (α-KG), a key metabolite regulating nitrogen homeostasis in catabolic pathways. It was thought that IDH1 might enhance lipid biosynthesis in liver or adipose tissue by generating NADPH, but we show here that lipid contents are relatively unchanged in both IDH1-null mouse liver and IDH1-deficient HepG2 cells generated using the CRISPR-Cas9 system. Instead, we found that IDH1 is critical for liver amino acid (AA) utilization. Body weights of IDH1-null mice fed a high-protein diet (HPD) were abnormally low. After prolonged fasting, IDH1-null mice exhibited decreased blood glucose but elevated blood alanine and glycine compared with wildtype (WT) controls. Similarly, in IDH1-deficient HepG2 cells, glucose consumption was increased, but alanine utilization and levels of intracellular α-KG and glutamate were reduced. In IDH1-deficient primary hepatocytes, gluconeogenesis as well as production of ammonia and urea were decreased. In IDH1-deficient whole livers, expression levels of genes involved in AA metabolism were reduced, whereas those involved in gluconeogenesis were up-regulated. Thus, IDH1 is critical for AA utilization in vivo and its deficiency attenuates gluconeogenesis primarily by impairing α-KG-dependent transamination of glucogenic AAs such as alanine. . The recent discovery of IDH1 and IDH2 mutations in human cancers (1) (2) (3) (4) has elicited new interest in defining IDH1's functions in vivo, which are still poorly understood. IDH1 is abundant in liver and was reported to participate in lipid biosynthesis in hepatocyte cytoplasm and peroxisomes (5, 6) . Mutant mice overexpressing IDH1 in liver and adipose tissue are obese, have fatty livers, and show elevated plasma triglycerides (TG) and cholesterol (7) . In tumor cells, IDH1 contributes to de novo lipogenesis by generating acetyl-CoA building blocks via the NADPH-dependent reductive carboxylation of α-KG to isocitrate (8) (9) (10) (11) . However, IDH1-null mice at steady-state are healthy and fertile, maintain normal body weight, and show no inflammatory symptoms (12) .
The liver maintains normal blood glucose levels through glycogenolysis and gluconeogenesis. Gluconeogenesis generates glucose from noncarbohydrate carbon substrates such as pyruvate, lactate, glycerol, and glucogenic amino acids (AAs). During prolonged fasting, the breakdown of skeletal muscle generates limited carbon resources in the form of AAs such as alanine. Hence, both fasting and feeding of a high-protein diet (HPD) can stimulate AA deamination and urea production in the liver (13) , where AA carbon skeletons are converted into glucose or lipids. For most AAs, the amino group is transferred to α-KG to generate glutamate and other α-keto acids. For example, alanine from blood or skeletal muscle can be transaminated to form pyruvate in hepatocyte cytosol. After transport into mitochondria, glutamate is oxidatively deaminated by glutamate dehydrogenase 1 (GLUD1) to produce α-KG and toxic ammonia. Ammonia is then eliminated via the urea cycle in the liver. Cytosolic α-KG produced by IDH1 is thus an important nitrogen transporter and prevents nitrogen overload (Fig. 1) . However, precisely how IDH1 functions in this process is unknown. In this study, we use IDH1-null mice and IDH1-deficient HepG2 cells to explore the roles of IDH1 in hepatic nitrogen metabolism and gluconeogenesis.
Results

IDH1 Deficiency Reduces Body Weight Gain and Fasting Blood Glucose
in Mice. Immunoblotting of WT mouse tissues revealed that IDH1 is abundant in liver, kidney, intestinal mucosa, white adipose tissues (WAT), and brown adipose tissues (BAT). IDH1 is also present at moderate levels in spleen, brain, and heart but is undetectable in skeletal muscle ( Fig. 2A) , consistent with reported mRNA expression patterns in GEO databases (GDS3113). To explore the role of IDH1 in nitrogen metabolism, newly weaned WT and IDH1-null mice were fed either a normal diet (ND) of standard chow or an HPD (50% protein), and body weights were recorded 2 times per wk for 8 wk. No significant differences were found in body weights of ND-fed WT and IDH1-null mice (Fig. 2B) . However, the body weights of HPD-fed IDH1-null mice were significantly lower than those of HPD-fed WT mice after 6 wk on HPD (Fig. 2C) . By 8 wk, the total amount of epididymal, inguinal, and perirenal WAT was decreased in both HPD-fed WT and IDH1-null mice compared with ND-fed mice, but no significant differences occurred between WT and IDH1-null mice (Fig. 2D) . Furthermore, the lipid contents of WT and IDH1-null mouse embryonic fibroblasts (MEFs) induced to undergo adipocyte differentiation in vitro were comparable (Fig. S1 ). We then monitored blood glucose under ND-fed, HPD-fed, and fasting conditions. Although blood
Significance
Isocitrate dehydrogenase 1 (IDH1) is abundant in liver. Although it was reported that IDH1 participates in lipid biosynthesis, we show here that IDH1 is instead critical for hepatic amino acid (AA) utilization. IDH1 catalyzes the generation of cytosolic α-ketoglutarate, which can be converted to glutamate in the liver via transamination. Both IDH1-null liver and IDH1-deficient HepG2 cells show defects in AA utilization. Because IDH1 mutations occur in various tumors and AA metabolism is critical for tumor cell growth, our elucidation of the functions of wild-type IDH1 in AA utilization should advance our understanding of how mutant IDH promotes malignancy.
glucose levels were similar in ND-and HPD-fed WT and IDH1-null mice, they were significantly decreased in IDH1-null mice compared with WT controls after fasting for 24 or 48 h after feeding with ND ( Fig. 2E) or HPD (Fig. 2F) . Survival of IDH1-null mice under prolonged fasting conditions was also impaired (Fig. 2G) . Thus, IDH1 is important for normal weight gain and blood glucose maintenance.
IDH1 Deficiency Increases Glucose Consumption in HepG2 Cells. To dissect IDH1's biological and metabolic functions, we generated IDH1-deficient HepG2 (IDH1 − HepG2) cells using the CRISPRCas9 system (14) . Immunoblotting confirmed that endogenous IDH1 was undetectable in IDH1 − HepG2 cells (Fig. 3A) . Because hepatic lipids are elevated in IDH1-transgenic mice (7), we analyzed lipid contents and glucose consumption in IDH1 − HepG2 cells. Although IDH1 loss did not significantly affect lipid content in HepG2 cells (Fig. S2) , IDH1 − HepG2 cells did consume more glucose than IDH1 + HepG2 cells (Fig. 3B ). When IDH1 + and IDH1 − HepG2 cells were cultured in medium containing abundant (25 mM) glucose, both lines grew to high cell density and showed similar cellular morphology. However, in DMEM with low (5.5 mM) glucose, IDH1 − HepG2 cells shrank and died as density increased, whereas IDH1 + HepG2 cells grew well (Fig. 3C ). When we examined the growth curves of IDH1 + and IDH1 − HepG2 cells cultured in medium containing 25 mM glucose, there were no deficits in proliferation or viability (Fig. 3D, Left) . However, after 6 d in medium with 5.5 mM glucose, the growth of IDH1 − HepG2 cells slowed, and their viability was significantly less than that of IDH1 + HepG2 cells (Fig. 3D, Right) . Thus, IDH1 is critical for normal glucose consumption and cell growth.
IDH1 Deficiency Increases Plasma AAs. The liver is crucial for lipid and nitrogen metabolism as well as for glucose metabolism. HE and PAS staining of livers of IDH1-null mice showed that IDH1 deficiency does not significantly affect hepatocyte morphology or glycogen content (Fig. S3 A and B) . Similarly, Oil Red O staining and TG quantitation indicated that IDH1 loss does not alter hepatic lipid contents ( Fig. S3 C and D) , a result confirmed in IDH1-null primary hepatocytes (Fig. S3E) .
To determine the role of IDH1 in nitrogen metabolism, we analyzed blood AAs using LC/MS-MS. Total blood AAs were increased ∼10% in IDH1-null mice compared with WT controls under ND-fed or fasting conditions (Fig. 4A) . However, the blood alanine level in fasted IDH1-null mice was significantly elevated compared with fasted WT mice (Fig. 4B) , whereas blood glycine in both ND-fed and fasted IDH1-null mice was increased significantly compared with ND-fed WT mice (Fig.  4C ). Blood glutamine was higher in IDH1-null mice than in WT controls under ND-fed, but not fasting, conditions (Fig. 4D) .
In the liver, the amino groups of AAs are removed to create α-keto acids that enter the metabolic mainstream as glucose precursors or Krebs cycle intermediates. Because free ammonia is toxic, liver enzymes convert ammonia to urea via the urea cycle. We found that plasma ammonia was decreased in fasted IDH1-null mice compared with fasted WT controls but that there was no difference under ND-fed conditions (Fig. 4E) . Plasma urea levels were comparable to the WT in both ND-fed and fasted IDH1-null mice (Fig. 4F) . Thus, IDH1 in liver is important for the maintenance of normal blood AAs.
IDH1 Deficiency Reduces AA Utilization. We next studied AA utilization in IDH1 − HepG2 cells. The results revealed that alanine uptake was slowed in IDH1 − HepG2 cells compared with IDH1 + HepG2 cells (Fig. 5A ), but the consumption of glutamine was similar (Fig.  S4A ). In addition, the growth and viability of IDH1 − HepG2 cells cultured in medium supplemented with 10 mM alanine but lacking glucose was significantly decreased compared with IDH1 + HepG2 cells (Fig. 5B) . These results mirrored those obtained when IDH1 − HepG2 cells were grown in low-glucose medium, again suggesting that alanine utilization is impaired in the absence of IDH1.
We then cultured IDH1 + and IDH1 − HepG2 cells in DMEM supplemented with 5% (vol/vol) dialyzed FBS plus various concentrations of glucose or various AAs. When the medium contained >2 mM glucose, IDH1
− HepG2 cells showed normal viability ( determined their viability. Both IDH1 + and IDH1 − HepG2 cells had similar rates of viability in control cultures containing DMEM supplemented with glucose and FBS, but neither line could survive in medium lacking both FBS and glucose, even when supplemented with glutamine, glutamate, aspartate, BCAA, or proline ( Fig. 5D and Fig. S4C ). Although IDH1 + HepG2 cells were able to grow in FBS-free DMEM containing alanine, IDH1 − HepG2 cells could not (Fig. 5D ). Pyruvate, a downstream metabolite of alanine, could partially rescue the growth of IDH1 − HepG2 cells in DMEM without glucose or FBS (Fig. 5D, Right) . Thus, IDH1 is vital for alanine catabolism.
IDH1 Deficiency Attenuates Gluconeogenesis in Liver. In the liver, alanine's amino groups are transferred to α-KG by glutamatepyruvate transaminase 1 (GPT1) to generate pyruvate and glutamate. Glutamate is then converted to α-KG in mitochondria via deamination by GLUD1. We found that ammonia production was decreased significantly in IDH1 − HepG2 cells compared with IDH1 + HepG2 cells when cultured in medium containing 10 mM alanine (Fig. 6A) . In cultured WT and IDH1-null primary hepatocytes, the addition of excess glutamine and alanine increased ammonia production by both lines, but this increase was ∼30% lower in the mutant cells when the DMEM contained 10 mM glutamine and ∼40% lower in the presence of 10 mM alanine (Fig.  6B) . Thus, IDH1 is required for normal AA utilization.
Ammonia produced by AA deamination is converted to urea via the hepatic urea cycle. We found that urea production was decreased in IDH1-null primary hepatocytes by only ∼10% compared with WT controls (Fig. 6C) . Pyruvate is generated from alanine by α-KG transamination mediated by GPT1, and pyruvate is a major substrate for gluconeogenesis. Glucose output was decreased by ∼25% in IDH1-null primary hepatocytes cultured in medium with 10 mM alanine, but this deficit could be eliminated by treatment of the cells with L-cycloserine (L-CS), an inhibitor of GPT1 (Fig. 6D) . Thus, IDH1 is critical for AA utilization leading to gluconeogenesis.
We next used microarray to determine gene expression patterns in IDH1-deficient liver. The mRNAs for enzymes involved in transamination or deamination, such as GPT1, glutaminase 2 (GLS2), and GLUD1, were decreased in IDH1-null liver, whereas mRNAs for enzymes involved in gluconeogenesis, such as fructose bisphosphatase 1 (FBP1), FBP2, and glucose-6-phosphatase, catalytic subunit (G6PC3), were increased (Fig.  7A) . Notably, mRNAs of IDH2, IDH3, and enzymes participating in the urea cycle or lipid biosynthesis were not altered in IDH1-null livers (Fig. 7A) . Quantitative PCR showed that the mRNA levels of GPT1, branched chain amino acid transaminase 1 (BCAT1), GLS2, and GLUD1 were decreased in IDH1-null livers compared with WT livers (Fig. 7B) , suggesting impaired transamination and deamination in the absence of IDH1. However, the mRNA levels of PCK1, FBP1/2, G6PC, and G6PC3 were increased in IDH1-null livers (Fig. 7B) , indicating that genes involved in gluconeogenesis were up-regulated due to a decrease in glucogenic substrates. Last, determination of intracellular α-KG and glutamate levels showed that both of these molecules were decreased in IDH1-null primary hepatocytes cultured in medium containing 10 mM alanine ( Fig. 7 C and D) . These data suggest that IDH1 deficiency reduces gluconeogenesis by impairing the utilization of AAs such as alanine.
Discussion
IDH1 is a cytosolic enzyme that converts isocitrate to α-KG while reducing NADP + to NADPH (15) . It was recently reported that IDH1 protects murine hepatocytes from endotoxin-induced oxidative stress by regulating the intracellular NADP + /NADPH ratio (12) . Because NADPH is a major cofactor for fatty acid biosynthesis, IDH1 transgenic mice showed markedly higher liver and serum levels of total TG and cholesterol compared with WT mice, suggesting that IDH1 might be a major NADPH producer for lipid biosynthesis (7) . Others have found that IDH1 mediates reductive glutamine metabolism for lipogenesis in hypoxic cells (9) . However, we have shown here that IDH1-null mice have normal body weights and hepatic lipid contents, although WAT was slightly decreased in ND-fed IDH1-null mice.
In this study, we observed that the body weight of IDH1-null mice was slightly lower than wild-type mice when fed with a 50% protein diet and that fasting blood glucose was decreased in + and IDH1 − HepG2 cells that were cultured in six-well plates (5 × 10 4 per well) in DMEM supplemented with dialyzed 5% FBS plus 5.5 mM or 25 mM glucose for the indicated times. The medium was changed every other day, and cell numbers and viability were determined 24 h after the medium change. Data are the mean ± SEM (n = 3), **P < 0.01, and ***P < 0.001 by Student's t test.
A B 
(mM) Fig. 4 . Increased blood amino acid levels in IDH1-null mice. Quantitation of blood levels of (A) total AAs, (B) alanine, (C) glycine, and (D) glutamine in 12-wkold WT (n = 8) and IDH1-null (n = 8) mice that were ND fed or fasted for 24 h. Fresh blood was collected by cardiac puncture and analyzed by LC/MS-MS. For other blood AAs, please see Table S1 . Quantitation of (E) serum ammonia and (F) urea in the mouse blood samples in A-D. Data are the mean ± SEM (n = 8).
For B-E, *P < 0.05 and ***P < 0.001 by Student's t test.
IDH1-null mice. In the future, it will be interesting to examine the effects of additional dietary stresses in IDH1-null mice, including further reduction in carbohydrate intake in the context of a high-protein diet. To further investigate these in vivo data, we found that IDH1 − HepG2 cells could not survive in low-glucose medium and that IDH1 − HepG2 cells consumed more glucose than IDH1 + HepG2 cells. This increased glucose consumption suggests that IDH1 deficiency impairs AA utilization, consistent with the slightly higher levels of blood AAs in IDH1-null mice compared with WT controls. Under fasting conditions, both blood alanine and glycine were increased in IDH1-null mice. Glutamine is synthesized mainly in skeletal muscle in vivo, but under prolonged fasting conditions, skeletal muscle switches to an alanine releasing phenotype to support gluconeogenesis in liver to maintain blood glucose. Our results show that blood glutamine was increased in IDH1-null mice only in the fed condition, which may relate to this metabolic switch. Moreover, IDH1 − HepG2 cells consumed less alanine than IDH1 + HepG2 cells, and excess alanine failed to improve the growth and viability of IDH1 − HepG2 cells. When these cells were cultured in medium containing 5% FBS but lacking glucose, the viability of IDH1 − HepG2 cells was not improved by AA addition, suggesting that the defect in AA metabolism was caused by IDH1 deficiency. This hypothesis was confirmed by the ability of alanine to support the growth of IDH1 + HepG2 cells but not IDH1 − HepG2 cells, in medium lacking both glucose and FBS. These data suggest that IDH1 deficiency increases glucose consumption while impairing AA utilization.
Glycogenolysis and gluconeogenesis contribute almost equally to hepatic glucose output in WT mice fasted overnight (16) , but the glycogen stores in these animals are consumed within 36-48 h of fasting. When fasting is prolonged, alanine is formed (mainly from skeletal muscle) by transamination of glucose-derived pyruvate. This alanine is transported to the liver where its carbon backbone is used for gluconeogenesis to stabilize blood glucose levels, a process known as the glucose-alanine cycle (17) . Our tissue distribution study showed that IDH1 expression is high in the liver but absent in skeletal muscle. After alanine is taken up by hepatocytes, it is converted to pyruvate by transamination via GPT1 and contributes to either gluconeogenesis, lipid biogenesis, or the Krebs cycle. In IDH1-null hepatocytes, α-KG production was reduced, alanine utilization was decreased, and GPT1 expression was down-regulated. Transamination of alanine converts α-KG to glutamate, which is deaminated by GLUD1 in mitochondria. GLUD1 is a mitochondrial matrix enzyme with a key role in nitrogen and glutamate metabolism. Ammonia produced by GLUD1 is converted to urea via the urea cycle. Therefore, we initially speculated that IDH1 deficiency might reduce gluconeogenesis from alanine by reducing α-KG-dependent transamination. However, we found that blood levels of free AAs were slightly increased in fasted IDH1-null mice when AA deamination was stimulated in the liver. These results suggested that mitochondrial α-KG might be transported into the cytosol to compensate for the decreased cytosolic α-KG in IDH1-null liver. Similarly, GLUD1 expression and production of ammonia and urea were all decreased only slightly in IDH1-deficient primary hepatocytes and IDH1 − HepG2 cells, whereas urea cycle enzymes were unchanged or slightly altered.
In addition to the liver, IDH1 is highly expressed in kidney, intestinal mucosa, and adipose tissues, where transamination is also very active. Amino acids can be used for lipogenesis in adipose tissues, which might explain why these tissues need high levels of cytosolic IDH1 and why overexpression of IDH1 promotes lipogenesis in adipose tissues and livers of IDH1 transgenic mice (7) . In contrast, in skeletal muscle and heart where cytosolic IDH1 is absent or very low, the mitochondrial α-KG is S4C . Data are the mean ± SEM (n = 3). For A and B, *P < 0.05, **P < 0.01, and ***P < 0.001 by Student's t test.
likely transported into the cytosol by the oxoglutarate carrier (OGC) SLC25A11 (18) . However, the levels of SLC25A11 are relatively lower in liver, and compensation by mitochondrial α-KG for the deletion of cytosolic IDH1 may be limited. The Krebs cycle in liver mitochondria supplies the majority of intermediates for the cytosolic biosynthesis of lipids and AAs. It has been reported that proliferating mammary epithelial cells catabolize glutamate primarily via transaminases to synthesize nonessential AAs and generate α-KG, suggesting that cytosolic α-KG is critical for cell proliferation (19) . Besides as an amino acceptor, α-KG is used as a cofactor for DNA modifying enzymes and histone demethylases, including ten-eleven translocation (TET) proteins and JmjC-domain containing histone demethylases (JHDM) (20, 21) . Supplementation with α-KG decreases DNA methylation and histone methylation, increases stem cell self-renewal, and suppresses cell differentiation (22) . Therefore, further studies are required to delineate the effects of IDH1 deficiency on the epigenetic state of specific cell types. Citrate is generated in the mitochondria, but it is an important substrate for biosynthesis in the cytosol upstream of IDH1 (23) . As a mitochondrial citrate carrier (CIC), SLC25A1 promotes the efflux of citrate from mitochondria into the cytosol (24) (25) (26) , where it can be converted into oxaloacetate and acetyl-CoA by ATP citrate lyase (ACL) or into isocitrate by aconitase 1 (Aco1) and then oxidized by IDH1 to generate NADPH and α-KG. Both acetyl-CoA and NADPH are the substrates for lipid biosynthesis, which is critical for cell proliferation, and therefore, SLC25A1 is an important molecule upstream of IDH1. It was reported that SLC25A1 is a direct transcriptional target of several p53 mutants and that inhibition of CIC activity blunts mutant p53-driven tumor growth (27) . Recessive mutations in the human SLC25A1 gene cause D,L-2-HG aciduria (28) . Although the origin of the D-and L-2-HG in these patients is still unclear, it may involve α-KG metabolism. Moreover, knockdown of Aco1 in 3T3-L1 cells diminishes cytosolic Aco1 activity and IDH1 mRNA levels and also impairs adipogenesis (29) , which may be due to the impaired production of cytosolic α-KG. Collectively, these observations provide further evidence that IDH1 may have important functions related at least in part to its role in cytosolic α-KG metabolism.
IDH1/2 mutations occur in grade II∼III glioma, secondary glioblastoma, acute myelogenous leukemia, enchondroma, and chondrosarcoma (30) (31) (32) (33) . Although mutant IDH1/2 enzymes have been widely studied, the biologic functions of WT IDH1 have been controversial despite the clarification of IDH1 enzymatic activity some decades ago. In our study, we have shown that the IDH1 product cytosolic α-KG is a key substrate for hepatic transamination and deamination and that IDH1 deficiency impairs hepatic gluconeogenesis by reducing alanine utilization. Thus, IDH1 is critical for normal AA utilization.
Materials and Methods
Mice. IDH1-null mice have been described previously (3) . The WT and IDH1-null male mice used in this study were of the C57BL/6 genetic background. Mouse protocols were approved by the Animal Care Committees of the University Health Network (Canada) or the Fourth Military Medical University (China). Mice were housed four to five per cage in an animal room with a 12-h on/off light cycle and free access to drinking water and mouse chow. WT and IDH1-null mice (4 wk old; n = 8 per group) were fed an ND of standard mouse chow (TD.91352; Teklad Laboratory) or an HPD (TD.90018; Teklad Laboratory) for 8 wk. Body weights were monitored 2 times per wk. Mice were killed at age 12 wk, and epididymal, inguinal, and perirenal WAT were dissected and weighed.
For fasting experiments, chow was removed, but water was provided ad libitum. Mice were killed by CO 2 asphyxiation within 24 h of showing early signs of health deterioration, i.e., before exhibiting significant distress. The humane endpoint was defined as body weight loss >20% relative to initial weight, accompanied by hunched posture, lethargy, and poor grooming.
Primary Mouse Hepatocytes. Hepatocytes were isolated by the modified collagenase method as previously described (34).
Immunoblotting. Tissues or cell samples were homogenized in RIPA buffer containing protease inhibitor mixture (Roche). Immunoblots were visualized with horseradish peroxidase (HRP)-conjugated secondary Ab (Santa Cruz Biotechnology; 1:5,000) using enhanced chemiluminescence (Millipore). Primary Abs were anti-IDH1 (goat polyclonal; Santa Cruz Biotechnology; 1:2,000), anti-acetylCoA carboxylase (ACC) (rabbit monoclonal; Cell Signaling Technology; 1:1,000), and anti-β-tubulin (mouse monoclonal; Cell Signaling Technology; 1:1,000).
Generation of IDH1-Deficient HepG2 Cells. CRISPR-Cas9 was used to generate IDH1-deficient (IDH1 − ) HepG2 cells. Briefly, DNA fragments 5′-CACCGTGTA-GATCCAATTCCACGTA-3′ and 5′-AAACTACGTGGAATTGGATCTACAC-3′ were annealed and treated with T4 kinase. The annealed DNA fragment was subcloned between BsmBI sites of LentiCRISPR vector to generate sgRNA targeted on human IDH1 (5′-TGTAGATCCAATTCCACGTA-3′) (14) . IDH1 CRISPR lentivirus was generated by transfecting LentiCRISPR-hIDH1, psAX2, and pVSVG plasmids into 293T cells. HepG2 cells were infected with IDH1 CRISPR lentivirus and selected by growth in 2 μg/mL puromycin for 2 wk. IDH1 expression was measured by immunoblotting as above. An sgRNA targeting EGFP was used to generate control (IDH1 + ) HepG2 cells.
LC-MS/MS Measurement of Blood Amino Acids. Mouse blood was dropped directly onto filter paper (Whatman) without additives and dried at room temperature. Determination of AAs from filter papers was performed using HPLC (LC; Shimadzu SI20AC) and tandem mass spectrometry (API 4000plus; AB SCIEX) as previously described (35) . Data processing and calculations were performed with ChemoView Software (AB SCIEX). Table S2 ). Data are expressed relative to levels in WT liver and are the mean ± SEM (n = 3). Quantitation of intracellular levels of (C) α-KG and (D) glutamate in IDH1 + and IDH1 − HepG2 cells cultured in DMEM lacking FBS and glucose but containing 10 mM alanine. Data are the mean ± SEM (n = 3). For B-D, *P < 0.05 and **P < 0.01 by Student's t test.
ammonia and urea concentrations were determined using commercial ammonia and urea assay kits (Sigma) according to the manufacturer's instructions. Absorbance at 340 nm was measured with a spectrophotometer (FlexStation 3; Molecular Devices). For primary hepatocytes, cells (5 × 10 5 ) were plated in 35-mm dishes and cultured overnight. Fresh DMEM (A14430-01; Gibco) supplemented with 5.5 mM glucose, 25 mM glucose, 10 mM glutamine, or 10 mM alanine (as indicated in Fig. 6 B and C) was added to cultures, and ammonia and urea production were measured colorimetrically after 2 h using kits (Sigma) according to the manufacturer's instructions.
For ammonia generated by HepG2 cells, IDH1 + and IDH1 − HepG2 cells were cultured in 35-mm dishes to 90% confluence. The medium was changed to DMEM (A14430-01; Gibco) with and without 10 mM alanine. Ammonia produced was measured after 2 h using the kits described above.
Endogenous Glucose Production. Primary mouse hepatocytes were cultured in six-well plates overnight. Cells were then pretreated for 6 h with DMEM lacking FBS and glucose, after which 10 mM alanine was added as a gluconeogenic substrate for 2 h. Glucose production in the medium was measured using an endpoint fluorimeter-coupled enzyme assay kit (Abcam).
Glutamate and α-KG Measurements. IDH1 + and IDH1 − HepG2 cells were cultured in 35-mm dishes to 80% confluence. The medium was changed to DMEM (A14430-01; Gibco) supplemented with 10 mM glucose and 5% FBS for 12 h, followed by culture in DMEM (A14430-01; Gibco) supplemented with and without 10 mM alanine for 6 h. Intracellular glutamate and α-KG were measured colorimetrically using a glutamate assay kit (ab83389; Abcam) and an α-KG assay kit (ab83431; Abcam) according to the manufacturer's instructions.
Growth Curves and Viability. To determine the effect of glucose concentration on the growth and viability of HepG2 cells, IDH1 + and IDH1 − HepG2 cells were inoculated in six-well plates (5 × 10 4 per well) and cultured in DMEM (A14430-01; Gibco) containing 5% dialyzed FBS (HyClone) plus 5.5 or 25 mM glucose. To determine the effects of alanine and glutamine on HepG2 cell growth, DMEM containing 5% dialyzed FBS plus 10 mM alanine or 10 mM glutamine was used. The medium was changed every other day, and cell numbers and viability were measured 24 h after each medium change using a Beckman Coulter Vi-CELL XR Cell Viability Analyzer.
Crystal Violet Staining. IDH1
+ and IDH1 − HepG2 cells (1.5 × 10 4 per well) were inoculated in flat bottom 96-well plates and incubated at 37°C in 5% CO 2 overnight. After washing with PBS, cells were incubated for 12 h in DMEM (A14430-01; Gibco; without glucose, glutamine, alanine, or pyruvate) with and without 5% dialyzed FBS and various concentrations of glucose, alanine, glutamine, glutamate, proline, or BCAA (ratio of leucine:isoleucine:valine = 2:1:1). After removal of medium, cells were fixed in 100 μL 4% paraformaldehyde followed by staining in 100 μL 0.5% crystal violet (Sigma) in 20% methanol for 2 h. The stain was removed by rinsing in water, and the plates were dried. Crystal violet was extracted from live cells with 100 μL methanol, and absorbance at 595 nm was measured with a spectrophotometer (FlexStation 3; Molecular Devices). IDH1 + HepG2 cells cultured in DMEM supplemented with 5% dialyzed FBS, 5.5 mM glucose, and 2 mM glutamine were assayed as a control.
Histological Analysis. Mouse tissues were fixed overnight at 4°C in PBS-buffered 4% (wt/vol) paraformaldehyde and embedded in paraffin. Cross-sections (5 μm) were prepared for hematoxylin-eosin (HE) and Periodic acid-Schiff (PAS) staining. For Oil Red O staining, mice were killed, and livers were immediately removed, cut into 10-μm sections, and fixed in 4% formaldehyde for 10 min. Sections were stained with 0.5% (wt/vol) Oil Red O solution in 60% isopropanol for 30 min, washed briefly with 60% isopropanol and PBS, and counterstained with hematoxylin before microscopy. Cellular lipids were detected by staining with Bodipy 493/503 (Invitrogen).
Statistical Analysis. All results are presented as the mean ± SEM of at least three independent experiments, each performed in duplicate or triplicate. Data were analyzed by the two-sided Student's t test using Prism 5.0 software (GraphPad Prism). Differences of P < 0.05 were considered statistically significant. P values are *P < 0.05, **P < 0.01, and ***P < 0.001.
